Bank hopes for sneak peek at Novo's new drug at capital markets day
According to Berenberg’s calculations, as much as 45% of Novo Nordisk’s current share price is based on Novo Nordisk’s pipeline of new drug candidates.
by MARKETWIRE
When Novo Nordisk holds its Capital Markets Day on March 7, private banking company Berenberg hopes to learn more about Novo Nordisk’s priorities and will focus on new drugs for the treatment of obesity and type 2 diabetes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
